Related Experiment Video
Updated: May 9, 2025

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
COVID-19 and Acute Myocardial Infarction: Exploring Clinical Factors and Treatment Expenditures
Soheila Rajaie1, Aziz Rezapour2, Masih Tajdini3
1Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Insights
Patients with acute myocardial infarction (AMI) and COVID-19 had higher mortality and longer hospital stays. However, direct treatment costs were similar between COVID-19 and non-COVID-19 AMI patients.
Area of Science:
- Cardiology
- Infectious Diseases
- Health Economics
Background:
- Acute myocardial infarction (AMI) occurring concurrently with COVID-19 presents complex clinical challenges.
- This co-morbidity impacts hospital resource utilization and patient outcomes.
- Understanding the direct treatment costs associated with this dual diagnosis is crucial for healthcare management.
Purpose of the Study:
- To investigate and analyze the direct treatment costs for patients experiencing acute myocardial infarction (AMI) alongside COVID-19.
- To compare these costs with those of AMI patients without COVID-19.
Main Methods:
- A cross-sectional study was conducted at Tehran Heart Center.
- Clinical data (symptoms, readmission, interventions) and treatment costs were analyzed.
- Mean medical costs were calculated for January-May 2022.
Main Results:
- The COVID-19 group had a higher mortality rate (24%) compared to the non-COVID-19 group (5%).
- Patients with COVID-19 experienced longer hospital stays (8.70 days vs. 6.31 days).
- Average total treatment costs were comparable between groups ($6384.54 vs. $6362.49).
Conclusions:
- Concurrent COVID-19 significantly increases in-hospital mortality for AMI patients.
- Longer hospital stays correlate with increased treatment costs.
- Despite higher mortality and longer stays, direct treatment costs for AMI patients with COVID-19 were not significantly different from those without COVID-19.
Background:
The concurrence of acute myocardial infarction (AMI) with COVID-19 can complicate the clinical conditions of patients and affect the patterns of hospital resource utilization. This study aimed to investigate and analyze the direct treatment costs of AMI patients with concurrent COVID-19.
Methods:
This cross-sectional study collected and analyzed clinical data, including symptoms, readmission, and interventions, and treatment cost data for all patients at Tehran Heart Center using SPSS26 software. The mean medical costs of patients from January through May 2022 were also calculated.
Results:
The COVID-19 group was composed of 72.9% male and 27.1% female patients, whereas the non-COVID-19 group consisted of 67.3% male and 32.7% female patients. Most of the patients in the COVID-19 group (60%) were in the elderly age group (>65 y). The length of stay was 8.70±5.84 days for the COVID-19 group and 6.31±4.42 days for the non-COVID-19 group. The mortality rate in the COVID-19 group was 24%, higher than the 5% rate in the other group. Additionally, the average total treatment costs were $6384.54±$6760.13 in the COVID-19 group and $6362.49±$4343.07 in the non-COVID-19 group (P>0.78 and P>0.050).
Conclusion:
The study found that the COVID-19 group had a significantly higher in-hospital mortality rate than the non-COVID-19 group. During the follow-up period, the incidence of complications (chest pain and heart failure) was higher in the non-COVID-19 group. It also showed that longer hospital stays resulted in higher treatment costs.
More Related Videos
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Pathophysiology of Cardiac Performance